An Open-label, Multidose Dose-escalation Study to Understand the Safety of CRISPR Gene-editing Therapy and Its Long-Lasting Effects in DMD Patients (MUSCLE)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
HuidaGene Therapeutics Co., Ltd.
Age
4–8
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Males ≥ 4 and ≤8 years at the time of signing informed consent, with clinical diagnosis of DMD;
DMD gene mutation types are deletions in exons 52, 52-61, or 52-63;
Able to walk at least 10 meters independently;
Willing to cooperate with muscle biopsy test;
Acceptable hematology, clinical chemistry, and urine laboratory parameters.
You may not be if
Presence of active infection;
Presence of DMD-associated cardiomyopathy manifestations;
Respiratory insufficiency requiring invasive or non-invasive ventilation;
Serious infections such as pneumonia, pyelonephritis, or meningitis within 4 weeks prior to receiving trial drug infusion;
Prior central nervous system surgery within 6 months before enrolment;
Use of any investigational drug, or exon-skipping drug (whether investigational or not) 6 months prior to Screening;
Previous treatment with any gene therapy or cell therapy (e.g., stem cell transplantation);
Any other conditions that would not allow the potential subject to complete follow-up examinations during the study and would, in the opinion of the investigator, make the potential subject unsuitable for the study.